Tenet (THC) director sells 12,350 shares at $183.44 — Form 4

Insider sale disclosed: Tenet Healthcare director Christopher S. Lynch reported a sale of 12,350 shares of Tenet Healthcare Corp (ticker: THC) on 08/28/2025 at a reported price of $183.44 per share.

Rhea-AI Filing Summary

Insider sale disclosed: Tenet Healthcare director Christopher S. Lynch reported a sale of 12,350 shares of Tenet Healthcare Corp (ticker: THC) on 08/28/2025 at a reported price of $183.44 per share. The Form 4 was signed by Chad J. Wiener as attorney-in-fact on 08/29/2025. The sale is reported as a direct disposition by the reporting person.

Positive

• Transaction was timely disclosed on Form 4, meeting Section 16 reporting requirements

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine insider sale disclosed; no additional context on ownership or reason provided.

The filing shows a director-initiated sale of 12,350 shares reported on Form 4, executed 08/28/2025 and filed 08/29/2025. This is a standard Section 16 disclosure meeting reporting requirements. The filing does not include information about remaining beneficial ownership, whether the sale was pre-arranged under a Rule 10b5-1 plan, or any change to board or executive roles, so governance implications are limited to disclosure compliance.

Securities Analyst

TL;DR: The transaction is a single disclosed sale; materiality to shareholders is unclear without ownership context.

The reported sale at $183.44 per share for 12,350 shares represents a clear disposition event but the Form 4 does not state post-transaction ownership totals beyond the shares sold or indicate if this represents a large percentage of the insider's holdings. Without additional position size or pattern of trades, this remains a routine disclosure rather than a clearly material market event.

Insider Trade Summary

Net Seller: 8 shares

Net Sell 1 txn

Insider Lynch Christopher S.

Role Director

Sold 8 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8	$183.44	$1K

Holdings After Transaction: Common Stock — 12,350 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Christopher S. Lynch report on Form 4 for THC?

He reported a sale of 12,350 shares of Tenet Healthcare Corp (THC) executed on 08/28/2025 at a price of $183.44 per share.

When was the Form 4 filed for the insider transaction by Christopher S. Lynch?

The Form 4 shows the transaction date as 08/28/2025 and was signed/filed on 08/29/2025 by Chad J. Wiener as attorney-in-fact.

Does the Form 4 indicate whether the sale was part of a 10b5-1 trading plan?

The filing does not specify that the transaction was made pursuant to a Rule 10b5-1 plan; no plan language is included in the provided content.

Is the reported ownership after the sale disclosed on this Form 4?

The Form 4 lists the shares sold and the transaction details but does not provide a complete post-transaction beneficial ownership total beyond the disposition entry in the provided content.

Who signed the Form 4 for Christopher S. Lynch?

The Form 4 was signed by Chad J. Wiener as attorney-in-fact for Christopher S. Lynch on 08/29/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/29/2025 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lynch Christopher S.

(Last) (First) (Middle)

14201 DALLAS PARKWAY

(Street)

DALLAS TX 75254

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TENET HEALTHCARE CORP [ THC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2025		S		8	D	$183.44	12,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Chad J. Wiener, as Attorney-in-fact for Christopher S. Lynch	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.